[go: up one dir, main page]

WO2009008461A1 - 性ホルモン感受性細胞増殖を原因とする疾患に対する医薬組成物 - Google Patents

性ホルモン感受性細胞増殖を原因とする疾患に対する医薬組成物 Download PDF

Info

Publication number
WO2009008461A1
WO2009008461A1 PCT/JP2008/062443 JP2008062443W WO2009008461A1 WO 2009008461 A1 WO2009008461 A1 WO 2009008461A1 JP 2008062443 W JP2008062443 W JP 2008062443W WO 2009008461 A1 WO2009008461 A1 WO 2009008461A1
Authority
WO
WIPO (PCT)
Prior art keywords
sex hormone
hormone sensitive
proliferation
pharmaceutical composition
hca
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/062443
Other languages
English (en)
French (fr)
Inventor
Kazuhiro Abeyama
Yasutoshi Yamada
Shinichi Nagayama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GRIFFIN BIOTECH Ltd
Original Assignee
GRIFFIN BIOTECH Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GRIFFIN BIOTECH Ltd filed Critical GRIFFIN BIOTECH Ltd
Priority to JP2009522664A priority Critical patent/JPWO2009008461A1/ja
Publication of WO2009008461A1 publication Critical patent/WO2009008461A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

　本発明の目的は、性ホルモン感受性の癌に対する抗腫瘍剤を提供することである。 　本発明により、ヒドロキシクエン酸(HCA)が、性ホルモン感受性の癌細胞の生育を抑制することが示された。HCAは、従来、急性毒性試験では、クエン酸よりも安全であることが示されており、HCAを有効成分として含有する本発明の抗腫瘍剤は、従来公知の抗腫瘍剤より副作用が小さいものと期待される。また、HCAを含む医薬組成物は、癌のみならず、性ホルモン感受性の細胞の増殖に起因するその他の疾患の治療にも役立つと考えられる。
PCT/JP2008/062443 2007-07-10 2008-07-10 性ホルモン感受性細胞増殖を原因とする疾患に対する医薬組成物 Ceased WO2009008461A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009522664A JPWO2009008461A1 (ja) 2007-07-10 2008-07-10 性ホルモン感受性細胞増殖を原因とする疾患に対する医薬組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-180960 2007-07-10
JP2007180960 2007-07-10

Publications (1)

Publication Number Publication Date
WO2009008461A1 true WO2009008461A1 (ja) 2009-01-15

Family

ID=40228632

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/062443 Ceased WO2009008461A1 (ja) 2007-07-10 2008-07-10 性ホルモン感受性細胞増殖を原因とする疾患に対する医薬組成物

Country Status (2)

Country Link
JP (1) JPWO2009008461A1 (ja)
WO (1) WO2009008461A1 (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011138565A1 (fr) * 2010-05-05 2011-11-10 Biorebus Association pharmaceutique contenant l'acide lipoïque, l'acide hydroxycitrique et une somatostatine a titre de principes actifs
FR2959668A1 (fr) * 2010-05-05 2011-11-11 Biorebus Association pharmaceutique contenant l'acide lipoique, l'acide hydroxycitrique et une somatostatine a titre de principes actifs
US20120101207A1 (en) * 2009-07-01 2012-04-26 Bridgestone Corporation Rubber-steel cord composite
EP3052133A2 (en) * 2013-10-03 2016-08-10 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for modulating autophagy in a subject in need thereof

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BUB J.D. ET AL.: "Adiponectin as a growth inhibitor in prostate cancer cells", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 340, no. 4, 2006, pages 1158 - 1166 *
FINNEY R.E. ET AL.: "Pharmacological inhibition of phosphatidylcholine biosynthesis is associated with induction of phosphatidylinositol accumulation and cytolysis of neoplastic cell lines", CANCER RES., vol. 60, no. 18, 2000, pages 5204 - 5213 *
KIYOSE C. ET AL.: "Relationship between Garcinia cambogia-Induced Impairment of Spermatogenesis and Meiosis-Activating Sterol Production in Rat Testis", J. CLIN. BIOCHEM. NUTR., vol. 38, no. 3, 2006, pages 180 - 187 *
KRIDEL S.J. ET AL.: "Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity", CANCER RES., vol. 64, no. 6, 2004, pages 2070 - 2075 *
MAEDA O.: "Zenritsusengan ni Taisuru Naibunpitsu Ryoho", UROLOGICAL NURSING, TOKI ZOKAN, 2002, pages 92 - 106 *
SZUTOWICZ A. ET AL.: "Lipogenetic and glycolytic enzyme activities in carcinoma and nonmalignant diseases of the human breast", BR. J. CANCER, vol. 39, no. 6, 1979, pages 681 - 687 *
XU Z.X. ET AL.: "Glucocorticoid induction of fatty-acid synthase mediates the stimulatory effect of the hormone on choline-phosphate cytidyltransferase activity in fetal rat lung", BIOCHIM. BIOPHYS. ACTA, vol. 1044, no. 1, 1990, pages 70 - 76 *
YU Z. ET AL.: "Evidence that an acetate pathway for cytosolic production of acetyl CoA for lipogenesis might exist in malignant prostate cells", FASEB JOURNAL, vol. 21, no. 6, 2007, pages A1098 - A1099 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120101207A1 (en) * 2009-07-01 2012-04-26 Bridgestone Corporation Rubber-steel cord composite
WO2011138565A1 (fr) * 2010-05-05 2011-11-10 Biorebus Association pharmaceutique contenant l'acide lipoïque, l'acide hydroxycitrique et une somatostatine a titre de principes actifs
FR2959668A1 (fr) * 2010-05-05 2011-11-11 Biorebus Association pharmaceutique contenant l'acide lipoique, l'acide hydroxycitrique et une somatostatine a titre de principes actifs
EP3052133A2 (en) * 2013-10-03 2016-08-10 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for modulating autophagy in a subject in need thereof
US11040052B2 (en) 2013-10-03 2021-06-22 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for modulating autophagy in a subject in need thereof

Also Published As

Publication number Publication date
JPWO2009008461A1 (ja) 2010-09-09

Similar Documents

Publication Publication Date Title
TNSN07341A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
UA95105C2 (ru) Применение производного лактамида для снижения токсичности в препарате, который может соприкасаться с кожей или глазами человека или животного, производные лактамида и способы их получения
MX2011012337A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de cancer y de otras enfermedades.
MX2011012122A (es) Derivados de tiofeno.
WO2008054454A3 (en) Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
MY143795A (en) Tetrahydropyridoindole derivatives
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2009109613A3 (en) 1-BENZYL-3-HYDROXYMETHYLINDAZOIιE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1
UA98804C2 (ru) Катехоламиновые производные и фармацевтическая композиция на их основе
MX2009004908A (es) Compuestos quimicos.
WO2008013987A3 (en) N-alkyl substituted piperazinylmethylquinazolinones and azepanylmethylquinazolinones
WO2011118976A3 (en) Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
WO2009109616A8 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
MX2009008084A (es) Derivados de 5,6,7,8-tetrahidropteridina como inhibidores de hsp90.
MX2012013606A (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de infecciones microbianas.
WO2011006935A3 (en) Tetrazole derivatives
WO2009109654A8 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1
WO2011058245A8 (fr) Nouveaux derives de mannopyranoside ayant une activite anticancereuse
UA96794C2 (ru) Глюкокортикоиды, способ их применения, способ лечения и фармацевтическая композиция на их основе
WO2009019708A3 (en) Pharmaceutical compositions and methods for the treatment of cancer
TW200616985A (en) Salicylthiazoles substituted by diphenylamine or diphenylamine derivatives, process for their preparation and their use
WO2009008461A1 (ja) 性ホルモン感受性細胞増殖を原因とする疾患に対する医薬組成物
MX342859B (es) Polisacarido de las semillas de tamarindo para usarse en el tratamiento de enfermedades inflamatorias.
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08791017

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009522664

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08791017

Country of ref document: EP

Kind code of ref document: A1